145 related articles for article (PubMed ID: 28984296)
1. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
[TBL] [Abstract][Full Text] [Related]
2. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract][Full Text] [Related]
3. Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Cheang MC; Martin M; Nielsen TO; Prat A; Voduc D; Rodriguez-Lescure A; Ruiz A; Chia S; Shepherd L; Ruiz-Borrego M; Calvo L; Alba E; Carrasco E; Caballero R; Tu D; Pritchard KI; Levine MN; Bramwell VH; Parker J; Bernard PS; Ellis MJ; Perou CM; Di Leo A; Carey LA
Oncologist; 2015 May; 20(5):474-82. PubMed ID: 25908555
[TBL] [Abstract][Full Text] [Related]
4. Relationships between Reproductive Risk Factors for Breast Cancer and Tumor Molecular Subtypes.
Nafissi N; Faraji M; Hosseini M; Shojaee L; Ziaei F; Akbari ME; Mousavie SH
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1767-1770. PubMed ID: 30049185
[TBL] [Abstract][Full Text] [Related]
5. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
[TBL] [Abstract][Full Text] [Related]
6. Advancing breast cancer subtyping: optimizing immunohistochemical staining classification with insights from real-world Taiwanese data.
Chang YT; Hong ZJ; Yu JC; Lin WZ; Huang TY; Tsai HH; Feng AC; Hsu KF; Huang CC; Chu CM; Liang CM; Liao GS
Am J Cancer Res; 2023; 13(11):5719-5732. PubMed ID: 38058819
[TBL] [Abstract][Full Text] [Related]
7. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
Watson J; Wang T; Ho KL; Feng Y; Mahawan T; Dobbin KK; Zhao S
Breast Cancer Res; 2023 Oct; 25(1):114. PubMed ID: 37789381
[TBL] [Abstract][Full Text] [Related]
8. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T; Lavado-Valenzuela R; Jimenez B; Pascual T; Gálvez F; Falcón A; Alamo MDC; Morales C; Amerigo M; Pascual J; Sanchez-Muñoz A; González-Guerrero M; Vicioso L; Laborda A; Ortega MV; Perez L; Fernandez-Martinez A; Chic N; Jerez JM; Alvarez M; Prat A; Ribelles N; Alba E
Front Oncol; 2019; 9():1178. PubMed ID: 31750258
[No Abstract] [Full Text] [Related]
9. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and Immunophenotypic Classification of Invasive Lobular Carcinoma with Histiocytoid Features.
Coty-Fattal Z; Minhas S; Butcher M; Agarwal I; LaBoy C; Blanco L; Novo J
Int J Surg Pathol; 2024 Jun; 32(4):719-725. PubMed ID: 37525567
[TBL] [Abstract][Full Text] [Related]
11. A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India.
Somal PK; Sancheti S; Sharma A; Sali AP; Chaudhary D; Goel A; Dora TK; Brar R; Gulia A; Divatia J
South Asian J Cancer; 2023 Apr; 12(2):104-111. PubMed ID: 37969672
[TBL] [Abstract][Full Text] [Related]
12. The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience.
Dank M; Mühl D; Pölhös A; Csanda R; Herold M; Kovacs AK; Madaras L; Kulka J; Palhazy T; Tokes AM; Toth M; Ujhelyi M; Szasz AM; Herold Z
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761848
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
14. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
[TBL] [Abstract][Full Text] [Related]
15. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists.
Johnson KS; Conant EF; Soo MS
J Breast Imaging; 2021 Jan; 3(1):12-24. PubMed ID: 38424845
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.
Hurson AN; Hamilton AM; Olsson LT; Kirk EL; Sherman ME; Calhoun BC; Geradts J; Troester MA
Breast Cancer Res Treat; 2023 May; 199(1):147-154. PubMed ID: 36892725
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients.
Yábar A; Meléndez R; Muñoz S; Deneo H; Freire J; Domínguez V; Carrasco-Navarro RM; Diaz ME; Velarde-López RE
Mol Clin Oncol; 2017 Apr; 6(4):503-509. PubMed ID: 28413656
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of hormone receptor-positive HER2-negative breast cancer.
Jin X; Zhou YF; Ma D; Zhao S; Lin CJ; Xiao Y; Fu T; Liu CL; Chen YY; Xiao WX; Liu YQ; Chen QW; Yu Y; Shi LM; Shi JX; Huang W; Robertson JFR; Jiang YZ; Shao ZM
Nat Genet; 2023 Oct; 55(10):1696-1708. PubMed ID: 37770634
[TBL] [Abstract][Full Text] [Related]
19. Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer.
Kang B; Lee J; Jung JH; Kim WW; Keum H; Park HY
Medicine (Baltimore); 2023 Aug; 102(34):e34772. PubMed ID: 37653831
[TBL] [Abstract][Full Text] [Related]
20. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]